{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["RMC-4630","cobimetinib"],["RMC-4630","osimertinib"]],"indication":"relapsed/refractory solid tumors","name":"NCT03989115","nct_id":"NCT03989115","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03989115. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"RMC-4630 and Cobimetinib for oral administration","label":"RMC-4630 and Cobimetinib","type":"EXPERIMENTAL"},{"description":"RMC-4630 and Osimertinib for oral administration","label":"RMC-4630 and Osimertinib","type":"EXPERIMENTAL"}],"collaborators":["Sanofi"],"completion_date":{"date":"2022-02-08","type":"ACTUAL"},"conditions":["Solid Tumor"],"enrollment":{"count":113,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"RMC-4630","otherNames":[],"type":"DRUG"},{"name":"Cobimetinib","otherNames":["GDC-0973, XL518"],"type":"DRUG"},{"name":"Drug: Osimertinib","otherNames":["Tagrisso","AZD9291"],"type":"DRUG"}],"last_update":"2023-06-26","lead_sponsor":"Revolution Medicines, Inc.","official_title":"Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2022-02-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Adverse Events (AEs).","timeFrame":"AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment."},{"measure":"Number of Participants With Dose Limiting Toxicities (DLTs)","timeFrame":"Cycle 1: Study Day 1 - Study Day 28 (28 days)"}],"references":[],"start_date":{"date":"2019-07-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC","url":"https://clinicaltrials.gov/study/NCT03989115"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03989115"}